The United Kingdom and the United States have reached a key bilateral deal that will keep zero duties on British medicine exports going into the US market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has agreed to boost spending on drugs through the National Health Service (NHS). This pledge secures that import taxes on these key goods will remain at nothing for a period of the next three years.
This agreement follows previous statements to significantly raise import taxes on patented drug imports, with increases mentioned up to 100%.
"This agreement with the UK bolsters the worldwide climate for innovative medicines and establishes much-needed balance to American-British drug exports," an announcement noted.
Trade Significance
Medicines represent one of the Britain's most significant export categories to the United States, which is easily the biggest market for leading UK drugmakers.
Statistics indicate that in the year leading up to September, the UK shipped pharmaceutical products totaling over eleven billion pounds to the US. This amount represented nearly one-fifth of British export trade in that period.
"This agreement safeguards jobs, increases capital expenditure and facilitates the UK to become a global hub for medical research," a minister commented.
Specific UK Commitments
The deal includes several key changes from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the price threshold at which it considers new medicines to be too expensive by a quarter.
- Increased NHS Spending: There is a aim to raise total NHS spending on drugs from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Payback Limit: The sum pharmaceutical firms must return to the NHS to control costs will be limited at 15%. Last year, repayments topped 20%.
Broader Context
The pact takes place against a protracted row between the pharmaceutical industry and the UK government over spending levels and approval rates.
These tensions were intensified by claims that American customers were paying significantly more for the equivalent treatments than consumers in the other developed nations.
In recent months, several major drug company projects in the UK have been halted or abandoned, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
A senior figure publicly accepted that the NHS had to invest a greater share on medicines, noting that its expenditure on drugs had declined as a share of its resources over the previous ten-year period.
